Tarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from Guggenheim

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a research note issued on Monday,Benzinga reports.

Other equities research analysts have also recently issued research reports about the stock. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Barclays increased their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. Finally, The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS traded down $1.46 during midday trading on Monday, hitting $46.39. The company had a trading volume of 79,849 shares, compared to its average volume of 592,494. The firm has a fifty day simple moving average of $51.87 and a two-hundred day simple moving average of $42.75. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -12.26 and a beta of 1.01.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the company. Creative Planning acquired a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth about $362,000. Allspring Global Investments Holdings LLC increased its holdings in Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after purchasing an additional 29,465 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares during the period. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at about $3,608,000. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 57.5% during the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock worth $595,000 after buying an additional 6,612 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.